The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
about
Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesStructural specializations of α(4)β(7), an integrin that mediates rolling adhesionVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabVedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel diseasePromising biological therapies for ulcerative colitis: A review of the literaturePatient considerations in the management of ulcerative colitis - role of vedolizumabNovel Therapies for Eosinophilic DisordersVedolizumab for inflammatory bowel disease: Changing the game, or more of the same?The multifaceted mast cell in inflammatory bowel diseaseHow Natalizumab Binds and Antagonizes 4 IntegrinsInterleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needsTherapeutic interventions in severe asthmaThe Dual Role of Neutrophils in Inflammatory Bowel DiseasesDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabEfficacy and safety of antiintegrin antibody for inflammatory bowel disease: a systematic review and meta-analysisIBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CASystematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.The safety of vedolizumab for the treatment of ulcerative colitis.Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.New Data on the Use of Biologic Agents for Crohn's Disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD MeetingAntibodies to watch in 2010Have we overestimated the benefit of human(ized) antibodies?Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.Exclusive antagonism of the α4 β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates.Vedolizumab for Crohn's disease.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.An integrin alpha4beta7•IgG heterodimeric chimera binds to MAdCAM-1 on high endothelial venules in gut-associated lymphoid tissueIntegrin antagonists are effective and safe for Crohn's disease: a meta-analysisPRISMA--efficacy and safety of vedolizumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.Introducing vedolizumab to clinical practice: who, when, and how?T cell-associated α4β7 but not α4β1 integrin is required for the induction and perpetuation of chronic colitisIdentification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Management of inflammatory bowel disease with oral serum-derived bovine immunoglobulin.Pharmacology of AMG 181, a human anti-α4 β7 antibody that specifically alters trafficking of gut-homing T cells.Investigational new drugs in the treatment of inflammatory bowel disease: a review.Blocking of α4β7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaquesPopulation pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease
P2860
Q24185835-348E3968-A529-4DB9-8D89-A9F0F48E91ACQ24611768-6192D702-EC28-4FFF-95EC-39463553371BQ24630083-0C7C8924-F356-4E82-B9B0-5AFD48EEF13EQ26750456-1DF4EB36-E15B-4DAF-A7A6-36F34093DC6CQ26752768-38498DD3-8096-4E40-8DFE-81DF220F368DQ26776139-17E2D735-FD36-42E2-B056-EF0A384CB75DQ26796432-59678229-D63B-4764-8DB6-5642795A32CEQ26799600-524BCE11-26D5-434A-B11F-9BCE1F05B0AFQ27021612-A02A69C6-8D70-4DE4-9EAF-B4F51AE761F6Q27026764-C1F9C05C-9018-4063-B0A2-9F4F08C3AD6EQ27679979-89582DAB-CD52-4178-BFD8-3B4E6F05F228Q28067081-42076297-40C2-40A8-9287-726F4F65AAC6Q28079238-866726A8-2DE3-4778-8DB9-1C464613947BQ28080144-5A5DEFE9-60F2-48DD-8E65-B2DB45D0849CQ28083872-73387FC3-B6EF-49A9-B469-62CC313A9924Q28084236-6DF63203-9E33-4E1B-A442-62701EC1A523Q28660580-D1603FD0-0A33-4B22-BE23-D673AD991801Q30234628-0011C679-564E-437F-B572-D0EDF41D1DA9Q30235363-679941E9-BE0E-48A4-84B3-EB824C2BD61AQ30248641-8CA67E67-6992-42F9-A0AA-790D5C2C3F13Q33607108-BAFA3814-9769-4E56-9DF7-055C042AFECFQ33612263-509A2449-9B47-4B17-9131-E5615D6AA12CQ33688243-382EE138-B93D-4D43-B6CE-AE2996E2E6F9Q34142714-F1799163-04F8-4F18-AF9C-CC2ACBE42AA2Q34243433-2BA4F520-7AA9-4942-9E3F-586001BA68E5Q34261526-E5A125D0-FFA1-49DC-BDC8-E39CE3820BE8Q34326912-8C54E676-B846-4515-AD41-56B2C1816C0EQ34518822-50D24ADA-392F-4134-A098-76F812683C56Q34837921-F6C3E695-0612-45AE-A090-78D8796B51EEQ35441308-EB224A74-63EB-4B27-BEF0-689ADEEB271DQ35473311-88F6EC2E-7BE5-40E1-ADC8-B9B24FAF93E6Q35530872-0C260AD0-1D7C-44C7-9FCD-8BA1A1855915Q35562290-3CB657C0-4008-4645-AB5F-00EF19A4ECEAQ35562422-9E8E8476-0957-4C82-8BBB-67BF18F32B7BQ35857404-C2488921-40E3-401E-9D9A-EA3A274F9F55Q36212191-15C64DC8-9EAC-4F96-B1BC-FA145EC82677Q36783977-E5499ADD-7535-4010-A35F-3E5B461DCB85Q36890446-BB2C2C89-008B-48C4-AC85-94FC36D15603Q36952767-41AF3066-4D49-4405-9FF6-84520D376C60Q37275504-B9FD9A0A-8BF5-454A-8734-0B583333EF71
P2860
The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The binding specificity and se ...... r inflammatory bowel diseases.
@ast
The binding specificity and se ...... r inflammatory bowel diseases.
@en
The binding specificity and se ...... r inflammatory bowel diseases.
@nl
type
label
The binding specificity and se ...... r inflammatory bowel diseases.
@ast
The binding specificity and se ...... r inflammatory bowel diseases.
@en
The binding specificity and se ...... r inflammatory bowel diseases.
@nl
prefLabel
The binding specificity and se ...... r inflammatory bowel diseases.
@ast
The binding specificity and se ...... r inflammatory bowel diseases.
@en
The binding specificity and se ...... r inflammatory bowel diseases.
@nl
P2093
P356
P1476
The binding specificity and se ...... r inflammatory bowel diseases.
@en
P2093
Dulce Soler
Eric R Fedyk
Li-Li Yang
Robert Egan
Tobias Chapman
P304
P356
10.1124/JPET.109.153973
P407
P577
2009-06-09T00:00:00Z